Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(R)to Remsima(R)? An Observational Study

Xue, LX; van Bilsen, K; Schreurs, MWJ; van Velthoven, MEJ; Missotten, TO; Thiadens, AAHJ; Kuijpers, RWAM; van Biezen, P; Dalm, VASH; van Laar, JAM; Hermans, MAW; Dik, WA; van Daele, PLA; van Hagen, PM

Xue, LX (corresponding author), Erasmus Univ, Internal Med, Rotterdam, Netherlands.; Xue, LX (corresponding author), Erasmus MC, Univ Med Ctr, Acad Ctr Rare Immunol Dis, Rotterdam, Netherlands.

FRONTIERS IN MEDICINE, 2020; 7 ():

Abstract

Background:Since the late '90s, infliximab (Remicade(R)) is being used successfully to treat patients with several non-infectious immune mediated infl......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索